Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00713947
Other study ID # P051021
Secondary ID AOM 05114
Status Withdrawn
Phase Phase 4
First received June 18, 2008
Last updated April 20, 2015
Start date April 2008
Est. completion date March 2010

Study information

Verified date April 2015
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

Low dose of aspirin is the main cause of gastro-duodenal ulcer. The best prevention is not definite particularly in patients without history of ulcer and infected by H. pylori.The aim of the study is to evaluate the gastric damage induced by aspirin in patients with H. pylori infection but who have any history of ulcer.


Description:

The aim of the study is to compare the protective effect of H. pylori eradication versus Pantoprazole versus placebo on the gastric damage induced by low dose of aspirin. Treatment are attributed by randomisation. Patients are followed for 6 months and gastric damage are evaluated by endoscopy at the end of this period.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2010
Est. primary completion date March 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients of more than 18 years old

- Coronarography or coronary imaging or supra-aortic arterial trunks ultrasound examination performed since less 7 months and having at least an arterial vascular stenosis

- Indication for aspirin treatment for at least 12 months (at the moment of the visit of inclusion) at a posology from 80 to 125 mg per day. The treatment must be prescribed since less than 7 months.

- Patient who had since less 7 month a positive Helicobacter Pylori serology.

- For the women in age to procreate, effective mode of contraception (oral contraception, surgical sterilization, coil)

- Patient having given an informed consent according to recommendation of the CPP (institutional ethical committee).

Exclusion Criteria:

- treatment by anti-coagulant, whatever its nature and its posology, by proton pump inhibitor, H2 receptor antagonists or antiacid having to be continued beyond the day of inclusion

- Treatment by methotrexate in progress or stopped since less 3 months.

- Time of more 7 months enters the beginning of the treatment by aspirin and the visit of inclusion

- Treatment by NSAID (even occasional or self medication) under or stopped since less 3 months.

- Treatment by anti-platelet drug (clopidogrel, ticlopidine, flurbiprofen, dipyridamole or antagonist of receptor GPIIb/IIIa) in progress or stopped since less than 10 days.

- Patient with a serious pathology compromising survival in the 6 month to come.

- Patient with renal or respiratory insufficiency or a hepatic pathology having a clinical repercussion.

- History of surgery of esophagus, stomach or duodenum.

- History of digestive tract bleeding or gastro-duodenal ulcer or esophagal ulcerating proven by endoscopy.

- Allergy known to clarithromycin.

- Psychiatric disorder not controlled by treatment.

- Patients all ready include in a therapeutic protocol or to be followed for 6 month.

- Alcohol consumption higher than 100gr. per day.

- Patient non suitable for participating in the protocol or to be followed for 6 month.

- History of intolerance to salicylate.

- Constitutional or acquired hemorrhagic disease

- Pregnant woman or nursing.

- Patient in emergency, people hospitalized without their assent, people without freedom, people without social health insurance.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
during one week for the active treatments
during one week for the active treatments placebo during 25 weeks
Pantoprazole
6 months at 20 mg
Placebo Formula 515
26 weeks, one tablet per day

Locations

Country Name City State
France Hotel Dieu Hospital Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure: severity of the ulcerated gastric lesions induced by the aspirin 6 months Yes
Secondary To measure: percentage of patients having had at least an ulcer 6 months Yes
Secondary To measure: the average of the ranks of lesion in antrum and corpus. 6 months Yes
Secondary To measure percentage of patients having had digestive clinical events 6 months Yes
Secondary To measure: the average of the ranks of severity of the hemorrhagic lesions and erosive lesions evaluated in antrum and corpus by two analogical scales of 150 mm 6 months Yes
Secondary To measure Percentage of patients having a hemorrhagic digestive of clinical expression or detected by the biological tests. 6 months Yes
Secondary To measure : Elements of the histopathologic score of Sydney 6 months Yes
See also
  Status Clinical Trial Phase
Completed NCT01274234 - OCT Evaluation of Healing of COMBO Stent Phase 1/Phase 2
Not yet recruiting NCT02591264 - Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3 N/A
Completed NCT03034148 - Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease N/A
Completed NCT00657436 - Myeloid-Related Protein in Evaluation of Acute Chest Pain in the Emergency Departement N/A
Completed NCT00714623 - The SCRIPPS DES REAL WORLD Registry N/A
Recruiting NCT00327041 - Monitoring Response to Antiplatelet Therapy Phase 4
Completed NCT03180931 - Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis N/A
Not yet recruiting NCT05647018 - In-hospital Clinical Outcome of Deferred Stenting Versus Immediate Stenting in the Management of Acute STEMI Presenting With High Thrombus Burden. Phase 2
Completed NCT00963781 - Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) Phase 4
Completed NCT01166685 - Safety and Efficacy Study Comparing 3 New Types of Coronary Stents Phase 4